How Does Getinge Company Work?

How is Getinge reshaping hospital care worldwide?

In early 2025 Getinge reported a record order intake above SEK 34.5 billion, driven by digitized operating rooms and cardiovascular solutions. The Swedish medtech leader supplies critical devices to ICUs and surgical departments globally.

With operations in over 135 countries and ~12,000 employees, Getinge is shifting from equipment sales to digital health services and biopharma production support to boost margins.

How does Getinge work? It combines advanced devices—ventilators, sterile reprocessing, ECMO—with services and data platforms to improve clinical outcomes; see Getinge Porter's Five Forces Analysis.

Getinge’s core operations center on vertically integrated medical technology, combining high-precision hardware and software across Acute Care Therapies, Life Science, and Surgical Workflows to improve clinical outcomes and lower total cost of care.

Business Areas

Operations are organized into three primary segments: Acute Care Therapies, Life Science, and Surgical Workflows, each addressing clinical and operational needs in hospitals and labs.

Value Proposition

Getinge focuses on improving patient outcomes while reducing total cost of care via integrated Smart Hospital solutions that automate sterile reprocessing and optimize surgical schedules.

Manufacturing Footprint

Global manufacturing hubs in Sweden, Germany, France, the United States, China, and Poland support production of Class III devices and complex systems under stringent quality control.

Distribution Model

Direct sales in mature markets and strategic distributors in emerging markets enable market coverage and tailored service models that drive recurring revenue.

Getinge’s vertically integrated model and Total Room ecosystem create high interoperability and switching costs, underpinned by investments in R&D and service contracts that drive lifecycle revenue and uptime guarantees.

Operational Highlights & Evidence

Key operational facts and metrics that illustrate how Getinge works and where value is generated.

• Manufacturing: six principal production countries supporting Class III device output and sterile processing equipment.
• Revenue drivers: mix of capital equipment sales and recurring service/consumables; service contracts often represent 20–30% of lifecycle revenue in comparable medtech peers (company disclosures vary by year).
• Supply chain: emphasis on high-grade medical components and ISO-compliant quality systems to meet regulatory requirements across markets.
• Product strategy: Total Room solutions bundle hardware, software, and services to enhance workflow efficiency and long-term partnerships with hospitals.

Getinge’s integrated approach—combining engineering, software, global manufacturing, and a hybrid sales network—supports scalable Getinge healthcare solutions that address personnel shortages, increase patient throughput, and strengthen the company’s market position; see this analysis of strategic initiatives in the Growth Strategy of Getinge.

Getinge’s revenue mix combines capital equipment sales, recurring consumables and multi‑year service contracts, with Acute Care Therapies as the largest contributor and growing recurring income from software and consumables.

Segmental Revenue Share

In fiscal 2024 Acute Care Therapies accounted for about 54% of net sales, Surgical Workflows about 33%, and Life Science roughly 13%.

Recurring Revenue Growth

Recurring revenue now represents over 45% of total income via service agreements and proprietary consumables tied to Getinge hardware.

Consumables Monetization

High‑margin disposables for ventilators and ECMO drive steady per‑procedure revenue streams and lock customers into repeat purchases.

Service Contracts

Multi‑year service and maintenance contracts provide predictable cash flow and aftermarket margins across installed bases in hospitals.

Software & SaaS

Tiered SaaS pricing for T‑DOC and Tegris introduced in 2025 shifts hospitals from capital expenditure to subscription/usage models.

Geographic Mix

Regional sales split: Americas 41%, EMEA 36%, APAC 23%, influencing pricing and service strategies.

Revenue levers combine product sales, consumables and services across Acute Care, Surgical Workflows and Life Science, with targeted SaaS uptake and consumable lock‑in improving lifetime customer value and margin stability.

Monetization Tactics and KPI Focus

Core monetization tactics emphasize recurring revenue expansion, installed‑base services, and software subscriptions while tracking ARPU, attach rates and service renewal rates.

• Increase consumable attach rate per device to raise per‑patient revenue.
• Grow installed base service penetration and multi‑year contract length to smooth cash flow.
• Scale SaaS adoption with tiered pricing tied to usage and hospital size.
• Prioritize Life Science bioprocessing as the fastest‑growing segment for higher‑margin sales.

Relevant reading on market positioning and peers: Competitors Landscape of Getinge

Getinge's recent milestones and strategic moves have strengthened its position across surgical, intensive care and transplant medicine, combining regulatory resilience with targeted acquisitions and operational regionalization.

Key Milestone: Paragonix Acquisition

In 2024 Getinge acquired Paragonix Technologies for an initial USD 477 million, expanding into the high-growth transplant medicine market and complementing its perfusion portfolio.

MDR Transition and Regulatory Scale

Getinge absorbed the costs of the new European Medical Device Regulation (MDR), a change that forced many smaller competitors out and reinforced Getinge company operations and market share.

R&D and Financial Discipline

Getinge maintains an R&D investment rate around 5 percent of sales, supporting product innovation across its medical technology and healthcare solutions portfolios.

Supply-Chain and Production Strategy

Post-pandemic, Getinge regionalized production and increased inventories of critical electronic components to improve Getinge workflow efficiency and reduce disruption risk.

Getinge’s competitive edge blends a massive installed base, reputation for reliability in zero-failure environments and integrated product breadth across the patient care journey.

Competitive Strengths and Strategic Implications

These strengths support Getinge’s role in critical care and public procurement, where ESG and lifecycle costs increasingly influence buying decisions.

• Installed base and service network create recurring revenue and high switching costs for hospitals.
• Broad product span—from OR to ICU to transplant—differentiates Getinge from niche competitors like Baxter or Dräger in specific segments.
• Regionalized manufacturing and higher component inventories reduced lead times and improved resilience after 2020–2023 supply shocks.
• Commitment to Net Zero by 2050 aligns procurement advantages with public healthcare systems focused on sustainability.

For a concise overview of the company’s guiding principles and structure see Mission, Vision & Core Values of Getinge.

Getinge holds a top-two global position in sterile reprocessing and mechanical ventilation, but 2025 brings headwinds from Chinese volume-based procurement and inflationary raw-material pressure; the company’s 2026 roadmap emphasizes Clinical Digitalization and Biopharma Expansion to stabilize and grow revenue.

Industry position

Getinge company operations place it among the leading medtech suppliers worldwide, with strong market shares in sterile reprocessing and ventilators and a diversified portfolio across acute care and bioprocessing.

Competitive landscape

Price pressure from China’s VBP and aggressive low-cost entrants are compressing margins; Getinge competes on engineering quality, service, and integrated solutions rather than lowest price alone.

Key strategic priorities

Management is prioritizing Clinical Digitalization and Biopharma Expansion, targeting AI-enabled ventilators and bolstering bioprocessing offerings to capture biologics and vaccine manufacturing demand.

Financial context

In 2024 Getinge reported revenue of approximately SEK 45 billion and operating margin pressures in 2025 linked to input-cost inflation and intensified tendering in key markets.

Future outlook depends on digital and M&A execution while protecting engineering-led value propositions and service revenue streams.

Risks and mitigation

Key risks include pricing erosion in China, raw-material inflation, and rapid AI-driven disruption; mitigation focuses on faster software cycles, targeted bolt-on acquisitions, and shifting sales mix toward consumables and services.

• Chinese VBP risk: accelerated price competition reducing device ASPs and margins
• Input-cost inflation: ongoing pressure on gross margins from raw materials and components
• AI disruption: need to accelerate software development to compete with tech-native medtech startups
• M&A integration: management appetite for bolt-ons raises execution risk but can speed capability build

Strategic levers include embedding AI decision support into ventilators to reduce ICU length of stay, expanding bioprocessing sales to capture growth in biologics, and monetizing data-enabled services to increase recurring revenue; see a focused analysis in Marketing Strategy of Getinge.